Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Pediatric low-grade glioma (pLGG): US-approved treatments and how Gulf families can access them

Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Pediatric low-grade glioma: the short answer

For pediatric low-grade glioma, the US FDA has approved one medicine covered on this page, for a specific group of patients: Ojemda. Ojemda is already on at least one Gulf list, so start by asking your hospital about local supply. Where a medicine is not registered in your country, the treating hospital can ask the national regulator for permission to import it for one named patient. Reserve Meds is a digital health company that helps families and hospitals with that process. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Ojemda.
Gulf registration (checked 17 October 2026): see each medicine below.
Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
Price: Quote on request.

What is pediatric low-grade glioma?

Gliomas are tumors that start in the glial cells that support nerve cells in the brain and spinal cord. Brain tumors are the second most common type of childhood cancer, after leukemia. Low-grade gliomas grow slowly and do not spread within the brain and spinal cord, but as they grow they press on nearby healthy brain and affect how it works. Most low-grade gliomas are treatable.^[1]

When a glioma comes back after treatment it is called recurrent; when it keeps growing despite treatment it is called progressive. Tumor testing for changes such as BRAF fusions now guides some treatment choices.^{[1, 2]}

Pediatric low-grade glioma in the Gulf

Saudi researchers profiled the tumors of 37 Saudi children with low-grade glioma. The KIAA1549-BRAF fusion was the most common change, found in 21 of the 37. This matters because Ojemda's US approval covers relapsed or refractory pLGG with a BRAF fusion or rearrangement, or a BRAF V600 mutation.^{[3, 2]}

On 17 October 2026, Ojemda was listed in the Abu Dhabi Department of Health drug code list and was not found in the SFDA drugs list.^{[4, 5]}

US FDA-approved medicines for pediatric low-grade glioma

Each medicine below is approved in the US for a specific group of patients. The wording follows the current US label. Your specialist decides whether any of them is right for the patient.

Ojemda (tovorafenib)
FDA-approved for patients aged 6 months and older with pediatric low-grade glioma that has come back or not responded to treatment, when the tumor has a BRAF fusion or rearrangement, or a BRAF V600 mutation. It is taken by mouth once a week. Approved under accelerated approval.^{[6, 2]}
US FDA approval: 23 April 2024. Gulf registers: Saudi Arabia: not found in the SFDA drugs list. Abu Dhabi: listed in the Abu Dhabi DoH drug code list. Checked 17 October 2026. Kuwait, Qatar and Oman: no public register checked.^{[5, 4]}
Country guides: Saudi Arabia, UAE, Egypt, Turkey, India, Pakistan

How families in the Gulf can access these medicines

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[7, 8]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
Reports that confirm the diagnosis, such as genetic, pathology or laboratory results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for pediatric low-grade glioma

Tell us the medicine, the country, and how to reach you. We reply within one business day. On WhatsApp we usually reply the same day.

Message us on WhatsApp Already have a case? Sign in

Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for pediatric low-grade glioma?

Yes. The medicine on this page has US FDA approval for a specific group of patients: Ojemda. The exact conditions are in the US label and are summarized above. Your specialist decides whether it fits.

Is Ojemda available in Saudi Arabia or the UAE?

Saudi Arabia: not found in the SFDA drugs list. Abu Dhabi: listed in the Abu Dhabi DoH drug code list. Checked 17 October 2026. Kuwait, Qatar and Oman: no public register checked. A listing in Abu Dhabi does not show federal UAE status, which we could not verify.

How can a family in the Gulf get Ojemda?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

Does my child's tumor need a BRAF test?

For Ojemda, yes. The US label asks doctors to confirm a BRAF fusion or rearrangement, or a BRAF V600 mutation, before treatment starts.

Sources for the last answer: ^[2]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.